ResearchHub | Open Science Community

Anna Frustaci

Author with expertise in Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia

Achievements

This user has not unlocked any achievements yet.

Key Stats

Upvotes received:

Publications:

(0% Open Access)

Cited by:

h-index:

i10-index:

Reputation

Biology

< 1%

Chemistry

< 1%

Economics

< 1%

How is this calculated?

Publications

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

Alessandra Tedeschi et al.Sep 1, 2024

The diffuse large B-cell lymphoma (DLBCL) variant of Richter transformation (DLBCL-RT) is typically chemoresistant with poor prognosis. Aiming to explore a chemotherapy-free treatment combination that triggers anti-tumour immune responses, we conducted a phase 2 study of atezolizumab (a PD-L1 inhibitor) in combination with venetoclax and obinutuzumab in patients with DLBCL-RT.

Genetics

Oncology

Paper

Genetics

Save

Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia

Valentina Griggio et al.Nov 5, 2024

Paper

Save

Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study

Francesco Autore et al.Nov 5, 2024

Paper

Save

Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway

Lodovico Bergamo et al.Nov 5, 2024

Paper

Save

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

John Seymour et al.Nov 5, 2024

Paper

Save

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Meghan Thompson et al.Nov 5, 2024

Paper

Save

Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

Alberto Fresa et al.Nov 5, 2024

Paper

Save

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Idanna Innocenti et al.Nov 5, 2024

Paper

Save

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Enrica Martino et al.Nov 5, 2024

Paper

Save

Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi

Gian Rigolin et al.Nov 5, 2024

Paper

Save